In the present study, our findings manifest the synergistic antitumor effects of the newly FDA-approved PARP inhibitor Niraparib and the antiangiogenic Brivanib in BRCA1/2 mutant rather than BRCA wild-type OC cells, and that the activation of both apoptotic and necroptotic pathways were involved in the anti-tumor effect. The gene discussed is PARP1; the disease is neoplasm.